• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'.

作者信息

van Bruggen F H, Nijhuis G B J, Zuidema S U, Luijendijk H J

机构信息

Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

出版信息

Expert Rev Clin Pharmacol. 2021 Feb;14(2):283-284. doi: 10.1080/17512433.2021.1874350. Epub 2021 Jan 19.

DOI:10.1080/17512433.2021.1874350
PMID:33428485
Abstract
摘要

相似文献

1
Response to letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'.对致编辑信的回复：关于“ClinicalTrials.gov上报告的PCSK9抑制剂试验中的严重不良事件和死亡：一项系统评价”
Expert Rev Clin Pharmacol. 2021 Feb;14(2):283-284. doi: 10.1080/17512433.2021.1874350. Epub 2021 Jan 19.
2
Letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'.致编辑的信：关于“ClinicalTrials.gov上报告的PCSK9抑制剂试验中的严重不良事件和死亡：一项系统评价”
Expert Rev Clin Pharmacol. 2021 Feb;14(2):281-282. doi: 10.1080/17512433.2021.1874346. Epub 2021 Jan 12.
3
Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review.ClinicalTrials.gov 上报告的 PCSK9 抑制剂试验中的严重不良事件和死亡：系统评价。
Expert Rev Clin Pharmacol. 2020 Jul;13(7):787-796. doi: 10.1080/17512433.2020.1787832. Epub 2020 Jul 13.
4
Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.前蛋白转化酶枯草溶菌素9型抑制剂导致不良神经认知结局的风险增加。
Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1). doi: 10.1161/CIRCOUTCOMES.116.003153.
5
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂：当前观点与未来展望。
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.
6
The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.前蛋白转化酶枯草溶菌素 9 丝氨酸蛋白酶抑制剂对原发性高胆固醇血症患者血脂水平和结局的影响：网状荟萃分析。
Eur Heart J. 2016 Feb 7;37(6):536-45. doi: 10.1093/eurheartj/ehv563. Epub 2015 Nov 17.
7
From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.从脯氨酰肽链内切酶枯草溶菌素 9 到其抑制剂：最新进展及其临床意义。
Eur Heart J Cardiovasc Pharmacother. 2016 Jan;2(1):44-53. doi: 10.1093/ehjcvp/pvv045. Epub 2015 Nov 29.
8
PCSK9 Inhibitors and Cardiovascular Disease: Impact on Cardiovascular Outcomes.PCSK9 抑制剂与心血管疾病：对心血管结局的影响。
Curr Drug Discov Technol. 2020;17(2):138-146. doi: 10.2174/1570163816666181211112358.
9
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.在患有糖尿病和血脂异常的人群中，丝氨酸蛋白酶 9 抑制剂的疗效和安全性。
Diabetes Obes Metab. 2019 Apr;21 Suppl 1:39-51. doi: 10.1111/dom.13636.
10
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.降脂治疗对非酒精性脂肪性肝病患者肝脏脂肪含量的影响：一项荟萃分析
Ann Intern Med. 2015 Jul 7;163(1):40-51. doi: 10.7326/M14-2957.

引用本文的文献

1
Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study.依洛尤单抗和阿利西尤单抗试验中基线失衡的定量评估：一项荟萃流行病学研究。
BMC Med Res Methodol. 2024 Jun 22;24(1):137. doi: 10.1186/s12874-024-02260-z.